Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
22
BHVN Quote, Financials, Valuation and Earnings
Last price:
$9.62
Seasonality move
:
7.51%
Day range:
$8.98 - $9.68
52-week range:
$7.48 - $46.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.70x
Volume:
3.3M
Avg. volume:
5.1M
1-year change:
-79.14%
Market cap:
$1.3B
Revenue:
--
EPS (TTM):
-$7.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BHVN
Biohaven Ltd.
|
$375.1K | -$1.54 | -- | -37.07% | $19.56 |
|
CAPR
Capricor Therapeutics, Inc.
|
$480K | -$0.54 | -100% | -240.39% | $44.56 |
|
EXEL
Exelixis, Inc.
|
$590.2M | $0.67 | 7.5% | 59.24% | $44.94 |
|
NEOG
Neogen Corp.
|
$208.5M | $0.06 | -9.84% | 800% | $8.17 |
|
NKTR
Nektar Therapeutics
|
$10.2M | -$2.79 | -64.22% | -1474.64% | $107.29 |
|
STXS
Stereotaxis, Inc.
|
$8.4M | -$0.06 | 43.53% | -30.79% | $4.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BHVN
Biohaven Ltd.
|
$9.61 | $19.56 | $1.3B | -- | $0.00 | 0% | -- |
|
CAPR
Capricor Therapeutics, Inc.
|
$25.40 | $44.56 | $1.2B | -- | $0.00 | 0% | 103.59x |
|
EXEL
Exelixis, Inc.
|
$44.37 | $44.94 | $11.9B | 18.68x | $0.00 | 0% | 5.55x |
|
NEOG
Neogen Corp.
|
$5.93 | $8.17 | $1.3B | 2,124.15x | $0.00 | 0% | 1.45x |
|
NKTR
Nektar Therapeutics
|
$57.69 | $107.29 | $998.1M | -- | $0.00 | 0% | 59.49x |
|
STXS
Stereotaxis, Inc.
|
$2.43 | $4.25 | $226.8M | -- | $0.00 | 0% | 7.16x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BHVN
Biohaven Ltd.
|
105.78% | 1.710 | 19.78% | 2.31x |
|
CAPR
Capricor Therapeutics, Inc.
|
17.61% | 1.632 | 5.44% | 3.50x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.460 | 1.59% | 3.47x |
|
NEOG
Neogen Corp.
|
27.22% | 2.315 | 63.43% | 1.93x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.157 | 16.97% | 4.07x |
|
STXS
Stereotaxis, Inc.
|
32.62% | 1.831 | 1.93% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BHVN
Biohaven Ltd.
|
-$1.1M | -$169.4M | -213.94% | -349.4% | -- | -$145.7M |
|
CAPR
Capricor Therapeutics, Inc.
|
-$494.7K | -$26.3M | -72.3% | -77.32% | -69.16% | -$23.7M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
|
NEOG
Neogen Corp.
|
$72M | -$16.1M | -30.61% | -41.21% | -7.69% | -$13.1M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
STXS
Stereotaxis, Inc.
|
$4.1M | -$5.2M | -141.59% | -218.3% | -69.75% | -$4.2M |
Biohaven Ltd. vs. Competitors
-
Which has Higher Returns BHVN or CAPR?
Capricor Therapeutics, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of -63.94%. Biohaven Ltd.'s return on equity of -349.4% beat Capricor Therapeutics, Inc.'s return on equity of -77.32%.
Company Gross Margin Earnings Per Share Invested Capital BHVNBiohaven Ltd.-- -$1.64 $297M CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M -
What do Analysts Say About BHVN or CAPR?
Biohaven Ltd. has a consensus price target of $19.56, signalling upside risk potential of 103.56%. On the other hand Capricor Therapeutics, Inc. has an analysts' consensus of $44.56 which suggests that it could grow by 75.42%. Given that Biohaven Ltd. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Biohaven Ltd. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHVNBiohaven Ltd.9 6 0 CAPRCapricor Therapeutics, Inc.8 0 0 -
Is BHVN or CAPR More Risky?
Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Capricor Therapeutics, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.632%.
-
Which is a Better Dividend Stock BHVN or CAPR?
Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Capricor Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHVN or CAPR?
Biohaven Ltd. quarterly revenues are --, which are smaller than Capricor Therapeutics, Inc. quarterly revenues of --. Biohaven Ltd.'s net income of -$173.4M is lower than Capricor Therapeutics, Inc.'s net income of -$24.6M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Capricor Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 103.59x for Capricor Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHVNBiohaven Ltd.-- -- -- -$173.4M CAPRCapricor Therapeutics, Inc.103.59x -- -- -$24.6M
-
Which has Higher Returns BHVN or EXEL?
Exelixis, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of 32.38%. Biohaven Ltd.'s return on equity of -349.4% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital BHVNBiohaven Ltd.-- -$1.64 $297M EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About BHVN or EXEL?
Biohaven Ltd. has a consensus price target of $19.56, signalling upside risk potential of 103.56%. On the other hand Exelixis, Inc. has an analysts' consensus of $44.94 which suggests that it could grow by 1.3%. Given that Biohaven Ltd. has higher upside potential than Exelixis, Inc., analysts believe Biohaven Ltd. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHVNBiohaven Ltd.9 6 0 EXELExelixis, Inc.9 9 0 -
Is BHVN or EXEL More Risky?
Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.
-
Which is a Better Dividend Stock BHVN or EXEL?
Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHVN or EXEL?
Biohaven Ltd. quarterly revenues are --, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Biohaven Ltd.'s net income of -$173.4M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 18.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 5.55x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHVNBiohaven Ltd.-- -- -- -$173.4M EXELExelixis, Inc.5.55x 18.68x $597.8M $193.6M
-
Which has Higher Returns BHVN or NEOG?
Neogen Corp. has a net margin of -- compared to Biohaven Ltd.'s net margin of 17.37%. Biohaven Ltd.'s return on equity of -349.4% beat Neogen Corp.'s return on equity of -41.21%.
Company Gross Margin Earnings Per Share Invested Capital BHVNBiohaven Ltd.-- -$1.64 $297M NEOGNeogen Corp.34.4% $0.17 $2.9B -
What do Analysts Say About BHVN or NEOG?
Biohaven Ltd. has a consensus price target of $19.56, signalling upside risk potential of 103.56%. On the other hand Neogen Corp. has an analysts' consensus of $8.17 which suggests that it could grow by 37.72%. Given that Biohaven Ltd. has higher upside potential than Neogen Corp., analysts believe Biohaven Ltd. is more attractive than Neogen Corp..
Company Buy Ratings Hold Ratings Sell Ratings BHVNBiohaven Ltd.9 6 0 NEOGNeogen Corp.1 3 0 -
Is BHVN or NEOG More Risky?
Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neogen Corp. has a beta of 1.986, suggesting its more volatile than the S&P 500 by 98.621%.
-
Which is a Better Dividend Stock BHVN or NEOG?
Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neogen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Neogen Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHVN or NEOG?
Biohaven Ltd. quarterly revenues are --, which are smaller than Neogen Corp. quarterly revenues of $209.2M. Biohaven Ltd.'s net income of -$173.4M is lower than Neogen Corp.'s net income of $36.3M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Neogen Corp.'s PE ratio is 2,124.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 1.45x for Neogen Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHVNBiohaven Ltd.-- -- -- -$173.4M NEOGNeogen Corp.1.45x 2,124.15x $209.2M $36.3M
-
Which has Higher Returns BHVN or NKTR?
Nektar Therapeutics has a net margin of -- compared to Biohaven Ltd.'s net margin of -301.29%. Biohaven Ltd.'s return on equity of -349.4% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital BHVNBiohaven Ltd.-- -$1.64 $297M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About BHVN or NKTR?
Biohaven Ltd. has a consensus price target of $19.56, signalling upside risk potential of 103.56%. On the other hand Nektar Therapeutics has an analysts' consensus of $107.29 which suggests that it could grow by 85.97%. Given that Biohaven Ltd. has higher upside potential than Nektar Therapeutics, analysts believe Biohaven Ltd. is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings BHVNBiohaven Ltd.9 6 0 NKTRNektar Therapeutics6 1 0 -
Is BHVN or NKTR More Risky?
Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.
-
Which is a Better Dividend Stock BHVN or NKTR?
Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHVN or NKTR?
Biohaven Ltd. quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Biohaven Ltd.'s net income of -$173.4M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 59.49x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHVNBiohaven Ltd.-- -- -- -$173.4M NKTRNektar Therapeutics59.49x -- $11.8M -$35.5M
-
Which has Higher Returns BHVN or STXS?
Stereotaxis, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of -86.59%. Biohaven Ltd.'s return on equity of -349.4% beat Stereotaxis, Inc.'s return on equity of -218.3%.
Company Gross Margin Earnings Per Share Invested Capital BHVNBiohaven Ltd.-- -$1.64 $297M STXSStereotaxis, Inc.54.94% -$0.07 $17.1M -
What do Analysts Say About BHVN or STXS?
Biohaven Ltd. has a consensus price target of $19.56, signalling upside risk potential of 103.56%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 74.9%. Given that Biohaven Ltd. has higher upside potential than Stereotaxis, Inc., analysts believe Biohaven Ltd. is more attractive than Stereotaxis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHVNBiohaven Ltd.9 6 0 STXSStereotaxis, Inc.3 0 0 -
Is BHVN or STXS More Risky?
Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.
-
Which is a Better Dividend Stock BHVN or STXS?
Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHVN or STXS?
Biohaven Ltd. quarterly revenues are --, which are smaller than Stereotaxis, Inc. quarterly revenues of $7.5M. Biohaven Ltd.'s net income of -$173.4M is lower than Stereotaxis, Inc.'s net income of -$6.5M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 7.16x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHVNBiohaven Ltd.-- -- -- -$173.4M STXSStereotaxis, Inc.7.16x -- $7.5M -$6.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 87.95% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 2.04% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 1.27% over the past day.
